Adverse Drug Reaction Patterns of First-line Anti-tubercular Drugs among Saharia Tuberculosis Patients: An Observational Study in Particularly Vulnerable Tribal Group of Madhya Pradesh, India-Reference-Cited by-同舟云学术

Adverse Drug Reaction Patterns of First-line Anti-tubercular Drugs among Saharia Tuberculosis Patients: An Observational Study in Particularly Vulnerable Tribal Group of Madhya Pradesh, India

Published:2023-10 Issue:4 Volume:67 Page:542-545
ISSN:0019-557X
Container-title:Indian Journal of Public Health
language:en
Short-container-title:

Author:

Mishra Prashant¹,Bhat Jyothi²³,Yadav Rajiv⁴,Sharma Ravendra Kumar⁵,Rao Vikas Gangadhar⁶

Affiliation:

1. Project Scientist B, ICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India

2. Scientist F, ICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India

3. Scientist F, Department of Microbiology and Molecular Biology, ICMR-National Institute of Traditional Medicine, Belagavi Karnataka, India

4. Scientist E, ICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India

5. Professor, Department of Economics, Ch. Charan Singh University, Meerut, Uttar Pradesh, India

6. Former Scientist G & Consultant, Department of Communicable Disease, ICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India

Abstract

Summary The Saharia tribe of Madhya Pradesh has a very high tuberculosis (TB) burden. However, there is no report of adverse drug reaction (ADR) available in patients receiving anti-TB chemotherapy in the community. Reporting and monitoring of ADRs among TB patients is still rare in marginalized communities. An observational prospective study was performed from November 2019 to June 2020 to assess the patterns of ADRs in 250 Saharia TB patients, who were prescribed Category-I daily DOTS (HRZE) by the physician. Both male and female participants equally experienced ADR during the treatment, but relatively more females (92.6%) than males (88.6%) reported ADR during Phase I. Out of 250 patients, 224 patients (89.6%) experienced one or more ADRs in Phase I. The central nervous system-related (75.6%) ADR was mostly reported followed by any gastrointestinal (74.4%), cardiovascular (49.2%) and any dermatological related (44.4%) ADRs. It is paramount to timely monitor and proactively manages ADRs pertaining to anti-TB drug treatment with minimal alteration in the treatment course.

Publisher

Medknow

Reference8 articles.

1. Pulmonary tuberculosis: A public health problem amongst the Saharia, a primitive tribe of Madhya Pradesh, Central India;Rao;Int J Infect Dis,2010

2. Pulmonary tuberculosis – A health problem amongst Saharia tribe in Madhya Pradesh;Rao;Indian J Med Res,2015

3. Prevalence Survey in India 2019-2021;National;Summary Report;,2022

4. Adverse drug reactions with first-line and second-line drugs in treatment of tuberculosis;Prasad;Ann Natl Acad Med Sci,2021

5. Adverse drug reactions in tuberculosis patients due to directly observed treatment strategy therapy: Experience at an outpatient clinic of a teaching hospital in the city of Imphal, Manipur, India;Sinha;J Assoc Chest Physicians,2013